Repaid in full the existing EIB Loans1 in an amount of approximately €62 million and completed repurchase of all 2,266,023 existing EIB Tranche A Warrants and 700,000 of existing EIB Tranche B Warrants2 (corresponding to approximately 22.7 million Underlying Shares) for a repurchase price of €50 million Issued the Tranche A Convertible Bonds (€35 million) and the Tranche B Amortized Bonds (€40 million), for an initial aggregate drawdown of €75 million under the Debt Financing Transaction3 with funds and accounts managed by BlackRock and Claret Capital PartnersDaix (France), New York City (New York, United States), June 12, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ('Inventiva” or the 'Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ('MASH”), today announced the completion, on June 12, 2026, of the following key steps of the transactions previously announced on June 2, 2026 (the 'Combined Transaction”): (i) the repayment in full of the EIB Loans and the repurchase of a portion of the  existing EIB Warrants; and (ii) the issuance of the Tranche A Convertible Bonds and the Tranche B Amortized Bonds, together with the Lenders’ Warrants, under the Debt Financing Transaction for net proceeds of €71,298,750.